Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; sodium starch glycollate type a; silicon dioxide; docusate sodium; sodium benzoate; titanium dioxide; hypromellose; macrogol 6000; iron oxide red - cipla finasteride 1 is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years.,cipla finasteride 1 is not indicated for use in women (see use in pregnancy and clinical studies) or children.

Malta - English - Medicines Authority

cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - finasteride - film-coated tablet - finasteride 5 mg - urologicals

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - finasteride 1mg - film coated tablet - 1 mg - active: finasteride 1mg excipient: docusate sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry brown oy-s-36500 polyvidone 30 pregelatinised maize starch sodium starch glycolate - · regen is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss. · regen is not indicated for use in women (see warnings and precautions, pregnancy) or children. regen is not effective in postmenopausal women with androgenetic alopecia.

United States - English - NLM (National Library of Medicine)

cipla usa inc. - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 1 mg - finasteride tablet, usp is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only . efficacy in bitemporal recession has not been established. finasteride tablet, usp is not indicated for use in women. finasteride tablet is contraindicated in the following: - pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5 α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. if this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. [see warnings and precautions (5.1), use in specific populations (8.1), how supplied/storage and handling (16) and patient counseling information (1

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; allura red ac aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350; lecithin - cipla ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; allura red ac aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350; lecithin - cipla ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: glyceryl behenate; magnesium stearate; maize starch; lactose monohydrate; purified water; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 6000 - cipla pain relief ibuprofen plus is used for temporary relief of acute moderate pain and inflammation

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 60 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 30 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.